Clinical trial investigators write to FDA urging approval of Capricor's deramiocel
The letter from trial investigators precedes a regulatory decision on the Duchenne muscular dystrophy therapy.
Read at Yahoo Finance →Full coverage · 6 outlets
- Yahoo Finance · lead
- StocktwitsNRIX Slumps 35% After-Hours - What’s Driving The Selloff?
- STATAhead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
- Fierce BiotechFDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
- Tech TimesFDA Panel Rejects Deramiocel Evidence as Lancet Validates Same Trial Data
- MSNCAPR stock rises as clinical trial investigators write to FDA urging approval for Deramiocel